Results 71 to 80 of about 88,420 (193)

Molecular cloning of multiple forms of the ovine B7-2 (CD86) costimulatory molecule

open access: yes, 2006
To facilitate analysis of the role of costimulatory molecules in the ovine immune system, we cloned and sequenced eight putative alternatively spliced transcripts of the sheep CD86 (B7-2) costimulatory molecule.
Beatriz Amorena   +13 more
core   +1 more source

Antibodies to the costimulatory molecule CD86 interfere with ultraviolet radiation-induced immune suppression

open access: yes, 1998
Although almost all of the energy contained within the ultraviolet (UV) wavelengths of solar radiation is absorbed within the epidermis and upper layers of the dermis, UV irradiation can suppress the immune response to antigens introduced at distant, non-
Pride, M. W.   +2 more
core   +1 more source

The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells

open access: yesPathology & Oncology Research, 2018
Micro-environment plays important role in the pathogenesis of CLL by providing protective niche for CLL cells. Several molecules play important role in communication between CLL cells and immune cells like CD86.Some of the data suggest that CLL patients with high CD86 level need earlier treatments and cells with higher CD86 expression has higher ...
Ferenc, Takács   +8 more
openaire   +2 more sources

CTLA4-Ig/CD86 interactions in cultured human endothelial cells: effects on VEGFR-2 and ICAM1 expression

open access: yes, 2015
Previous studies have reported the presence of CD86 (B7.2) costimulatory molecule on endothelial cells (ECs) and recent data have shown that CTLA4-Ig (abatacept), used as a biological agent in rheumatoid arthritis, interacts with CD86 expressed on ...
MONTAGNA, PAOLA   +8 more
core   +1 more source

CD86 immunohistochemical staining for the detection of Talaromyces marneffei in lesions

open access: yesMicrobiology Spectrum
Talaromycosis is an invasive fungal disease caused by the pathogenic thermodimorphic fungus Talaromyces marneffei (TM), which is often overlooked in tropical and subtropical regions of Asia. In view of the diversity of clinical manifestations in patients
Jinling Fang   +3 more
doaj   +1 more source

A novel bispecific antihuman CD40/CD86 fusion protein with t-cell tolerizing potential.

open access: yes, 2004
Contains fulltext : 57237.pdf (Publisher’s version ) (Open Access)Clinical trials designed to achieve tolerance in humans by selectively antagonizing one of the T-cell costimulatory pathways, CD40-CD40L or CD80/CD86-CD28, are pending ...
Louis Boon   +17 more
core   +1 more source

Results of meta-analysis for CD86 polymorphisms and cancer.

open access: yes, 2014
aresults for female versus male;P, p value for heterogeneity test.Results of meta-analysis for CD86 polymorphisms and cancer.
Houjie Liang (319420)   +11 more
core   +1 more source

Costimulatory molecules CD80 and CD86 in the rat; tissue distribution and expression by antigen-presenting cells

open access: yes, 1998
The CD28-CD80/CD86 costimulatory pathway provides a critical signal for T cell activation. Only recently rat CD80 and CD86 have been cloned and monoclonal antibodies have been generated.
Peter J C van Breda Vriesman   +3 more
core   +1 more source

CD206 was expressed in a subpopulation of microglia distinct from KS+CD86- cells.

open access: yes, 2013
Sequential thin sections were subjected to immunohistochemical analyses (A). The spinal cord sections of SOD1G93A mice at 15 weeks were stained with KS (B), CD86 (C) and CD206 (D). Arrows, KS+CD86− microglia; arrowheads, KS–CD206+ microglia. Bars, 50 µm.
Tomohiro Ohgomori (426726)   +15 more
core   +1 more source

Engineered Exosome‐Based Senolytic Therapy Alleviates Stroke by Targeting p21+CD86+ Microglia

open access: yesExploration
Stroke remains the leading cause of neurological mortality and disability worldwide, with post‐stroke inflammation significantly hindering neural repair. Despite its critical impact, mechanism‐based therapeutic strategies are scarce.
Jialei Yang, Shipo Wu, Miao He
doaj   +1 more source

Home - About - Disclaimer - Privacy